Abstract
Retroviral vectors have been widely used as gene delivery vehicles for cancer gene therapy. However, insufficient levels of gene delivery with replication defective vectors have severely limited their efficacy for clinical protocols using direct in vivo delivery. Therefore, we have investigated the potential of developing replication-competent and semi-replication competent retroviruses for cancer gene therapy. Given recent adverse events in patients receiving replication defective vectors for modification of cells ex vivo, inclusion of multiple safety features are clearly necessary if such a vector is to pursued for in vivo delivery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
